Top 10 highest paid pharma CEOs
The pharmaceutical industry is worth around $1.702trn worldwide, but which CEOs across the world took the most money home last year?
10 | Werner Baumann
Werner Baumann is CEO of Bayer, a company with 118,900 employees, which was founded in 1963 in Barmen, Germany. Baumann joined the company in 1988. He was CFO of Bayer AG as of 2010 and then carried the title of Chief Strategy and Portfolio Officer and Chairman of the Board of Management before becoming CEO in 2016. In 2016, Baumann took home $6.6mn. Bayer is a growing company, which made $25.27bn in 2016.
9 | Olivier Brandicourt
Oliver Brandicourt is CEO of Sanofi. The company was founded in 2004 and Brandicourt joined in 2015. At this point he boasted nearly 30 years of experience in the pharmaceutical industry. He is a qualified physician who worked at Pfizer for 13 years and served as CEO of Bayer Healthcare AG before becoming CEO of Sanofi. In 2017, Brandicourt took home $11.6mn. Sanofi made a profit of $36.57bn in 2016 and currently employs 110,000 people.
8 | Severin Schwan
Severin Schwan is CEO of Roche, the company that was founded in 1896. Roche currently employs 78,604 people and in 2016, the company made $50.11bn. Schwan joined the company in 1993 as a trainee in the corporate finance office, and became CEO in 2006. Last year he took home $13.42mn.
7 | John Milligan
John Milligan is CEO of Gilead Sciences, a California-based company which was founded in 1987 and currently employs 9,000 people. The company made $30.39bn in 2016. Milligan joined Gilead in 1990. Previously, he had worked in many different positions in the biotechnology industry. In 2000, he became President of Corporate Development before being made CEO in 2016. Last year Milligan took home $13.9mn.
6 | Joseph Jimenez
Joseph Jimenez is the current CEO of Novartis, a company which resulted from the merger of Cieba-Geigy and Sandoz Pharmaceutical in 1996. It now employs 118,700 people and made $48.52bn in 2016. Jimenez joined Novartis in 2007 as Division Head before being made CEO in 2010. His previous experience included having been head of HJ Heinz Company’s North American company from 2002-2006. In 2016, Jimenez took home $14.15mn.
5 | Kenneth Frazier
Kenneth Frazier is the CEO of Merck & Co, a company founded in New York in 1891, which now employs 55,200 people. Merck & Co made $39.80bn in 2016. Frazier joined the company in 1992. Prior to this, he worked as a lawyer specialising in public affairs. In 2011, Frazier became CEO and his take-home pay in 2016 totalled $17mn.
4 | Richard Gonzalez
Richard Gonzalez is the CEO of AbbVie, which employs 29,000 people. AbbVie is a ‘spin-off’ of Abbot Laboratories which separated into two companies in 2013 allowing AbbVie to specialise in products such as diagnostic equipment and nutrition products, while Abbott focusses on research. Gonzalez has been CEO since then and last year the company made $25.56bn with Gonzalez taking home $18.18mn.
3 | Alex Gorsky
Alex Gorsky is the CEO of Johnson & Johnson. The company was founded in 1886 and became a publicly traded company in 1944. It has 127,100 employees and last year made $71.89bn. Gorsky joined the company in 1988 as a sales representative for Janssen, a company within Johnson & Johnson. He gained experience in management, sales and marketing before becoming president of Janssen and then the Company Group Chairman of Johnson & Johnson throughout Africa, the Middle East and Europe. He became CEO in 2012. Last year Gorsky took home $21.2mn.
2 | Jeffrey M. Leiden
Jeffrey M. Leiden is CEO of Vertex Pharmaceuticals. The company was founded in 1989 and currently employs 1800 people and last year turned a profit of $1.6bn. Leiden is a scientist and physician with a degree from the University of Chicago. For much of his career, he worked as a molecular biologist and cardiologist and he spent the last three decades working to improve the pharmaceutical and biotech industries. Leiden joined Vertex in 2000 and last year he took home $28.1mn.
1 | Leonard S. Schleifer
Leonard S Schleifer is CEO of Regeneron Pharmaceuticals. The company currently employs 5,400 people and made a profit last year of $5.2bn. Schleifer founded Regeneron in 1988 and last year he took home $47,462,526. Prior to founding Regeneron he was educated at Cornell University and the University of Virginia and is a licensed neurologist by the American Board of Psychiatry and Neurology.